Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Skip to article
Contents · Peripheral SpA
Chapter 9 · Measurement

Measuring Peripheral Arthritis, Enthesitis, Dactylitis and Patient Impact

Use DAPSA44 for its intended peripheral arthritis domain and complement it with enthesis, dactylitis, organ and patient-impact assessments.

Open accessEvidence reviewed:
On this page

Measurement should describe the decision

A reproducible score is valuable because it makes change visible. It becomes misleading when its domain is forgotten. Peripheral SpA can involve arthritis, enthesitis, dactylitis, axial disease and extra-musculoskeletal conditions. No single joint-oriented composite captures all of that. Choose an instrument for the problem being followed, then record the important domains it does not cover.

Before treatment, define both an inflammatory target and a patient-valued target. “Fewer swollen joints” and “able to walk through the workday” are related but different outcomes. Their disagreement at follow-up is useful information, not a failure of measurement.

Joint counts: name the examination

Record swollen and tender joints separately with the specified count system. A 66/68-joint assessment and a 44-joint assessment have different coverage. The same numeric result does not necessarily represent the same disease burden. A short count that omits the feet can miss important peripheral activity.

Examination technique and attribution matter. Distinguish tenderness from swelling, bony enlargement from synovitis, and a joint lesion from nearby tendon pathology. For serial assessments, use a consistent approach and record uncertainty at individual sites. Keep the actual locations available: a composite can hide the difference between two newly swollen ankles and two persistently tender finger joints.

ASAS-SPARADISE: a current published development

ASAS-SPARADISE selected DAPSA44 for disease activity related to peripheral arthritis in axSpA/pSpA clinical research. The main recommendation was published online in Annals of the Rheumatic Diseases on July 6, 2026. [1] It should no longer be described merely as ongoing work or a congress proposal.

The supporting comparative analysis used individual data from 13 randomized trials, including axial trials restricted to participants with peripheral arthritis and peripheral SpA trials. Composite measures generally performed better than single-item measures, with DAPSA44 showing consistent measurement properties. That analysis was published in September 2026. [2] These are measurement findings; they do not demonstrate that a DAPSA44-directed prescribing strategy improves every clinical outcome.

How DAPSA44 is calculated

The official ASAS implementation uses:

DAPSA44 = 1.3 × tender joint count (44) + 1.3 × swollen joint count (44) + patient joint pain (0–10) + patient global assessment (0–10) + CRP (mg/dL). [3]

The factor is applied to each 44-joint count. CRP reported in mg/L must be divided by 10 before entering a formula that expects mg/dL. Do not substitute a 28-joint count or omit the conversion while retaining the DAPSA44 name. The official calculator handles the stated laboratory unit and links the instrument’s source publications.

For an illustrative calculation, tender count 3, swollen count 2, pain 4, global 3 and CRP 10 mg/L give 1.3 × 3 + 1.3 × 2 + 4 + 3 + 1 = 14.5. This example teaches units and arithmetic; it is not a treatment recommendation. Retain the five input values with the total so a later reader can understand what drove the score.

Interpretation has limits

The ASAS calculator displays established DAPSA activity bands: remission at 4 or below, low above 4 through 14, moderate above 14 through 28, and high above 28. [3] A band is a description under that instrument. It does not certify remission of enthesitis, dactylitis, axial disease, psoriasis, IBD or uveitis.

DAPSA44 is not numerically interchangeable with original DAPSA calculated from full joint counts. Keep the instrument name visible when comparing visits or studies. A change in count coverage should not be concealed as a biological trend. Missing CRP is missing information; silently entering zero creates an apparently complete result that was never measured.

Enthesitis: standardize sites and preserve context

Clinical indices such as the Leeds Enthesitis Index count tenderness at defined sites. LEI was developed in PsA; other indices have different anatomical coverage and histories. [4] Use one consistently, add the clinically important sites it omits, and describe uncertainty about inflammatory attribution. A score records what the examination found, not a definitive mechanism for each tender location.

Ultrasound can complement the examination when discordance matters. The published DEUS Enthesitis Index combines clinical and ultrasound findings in axSpA/PsA and remains a distinct assessment approach with its own validation context. [5] It should not be presented as a universal replacement for clinical assessment or as an established treatment-escalation rule for non-psoriatic pSpA.

Dactylitis: more than a joint count

Record affected digits, tenderness and whether enlargement is currently inflammatory or residual. The Leeds Dactylitis Index was developed to quantify digit swelling and tenderness in PsA. [6] In routine care, a consistently recorded digit count with a clear description may be more informative than an inconsistently performed elaborate measure.

A dactylitic digit can impair grip, footwear and walking even when the joint composite is relatively low. Follow the same digit over time and distinguish improvements in pain, swelling and function. Do not infer whole-digit resolution merely because the tender joint count improved.

Patient impact belongs alongside activity

Measure pain and global assessment, but ask what they mean in this patient. Fatigue, poor sleep, work demands, structural damage and noninflammatory pain may influence responses. These are clinically important and deserve treatment; they do not automatically establish uncontrolled synovitis.

Choose a practical functional outcome, such as walking distance, ability to stand, hand use or a task that matters to the patient. Use validated functional or impact instruments where appropriate and keep wording and recall periods consistent. Patient and clinician assessments may diverge because they are observing different aspects of disease, not because one participant is necessarily mistaken.

A minimum longitudinal dataset

DomainRecord at each meaningful reviewInterpretation safeguard
ArthritisNamed joint counts, sites and DAPSA44 components when usedCheck coverage and CRP units.
EnthesesSpecified clinical index plus important additional sitesTenderness is not uniquely inflammatory.
DactylitisDigits, tenderness and swellingResidual enlargement differs from active inflammation.
Other domainsAxial, skin/nail, bowel and eye statusA joint score does not represent these domains.
Impact and safetyFunction, patient priority, adverse effects and adherenceImproved activity may not resolve every limitation.

When a number changes, inspect its components and the patient’s experience before changing therapy. The most useful measurement system creates a faithful longitudinal record and makes discordance easier to investigate. It does not turn multidomain care into a single automatic threshold.

Evidence in context

Source status checked October 6, 2026. Population applicability and publication maturity are separate judgments.

Scrollable evidence table

SourcePopulation and phenotypeDesign and statusApplicabilityClinical implicationImportant limitationLast checked
ASAS-SPARADISE [1]AxSpA/pSpA with peripheral arthritisInstrument-selection project; peer-reviewed July 2026Peripheral arthritis researchDAPSA44 endorsed for this domainNot a universal multidomain score or prescribing algorithm2026-10-06
13-trial analysis [2]Axial trials with arthritis subgroup plus pSpA trialsSecondary measurement analysis; peer-reviewed September 2026Mixed relevant trial populationsComposites outperform some single measuresTrial populations and existing available measures2026-10-06
Official DAPSA44 implementation [3]44-joint examination and patient/lab inputsOfficial implementation linked to peer-reviewed developmentCorrect computationUse 1.3 factors and CRP mg/dLActivity bands do not certify all-domain remission2026-10-06
LEI [4]PsAInstrument development; peer-reviewedPsA-derived enthesis assessmentStandardized tenderness sitesLimited site coverage; pain mechanisms can confound2026-10-06
DEI [5]AxSpA and PsACross-sectional index development; peer-reviewedMixed SpA assessmentCombines clinical and ultrasound informationFurther longitudinal/strategy validation needed2026-10-06
Dactylitis instrument [6]PsAInstrument development; peer-reviewedPsA-derived domain measureQuantifies digit swelling and tendernessDoes not establish diagnosis or overall disease activity2026-10-06

Sources

  1. Ramiro et al. Instrument selection for peripheral arthritis: ASAS-SPARADISE (2026)
  2. Capelusnik et al. Measurement properties in 13 randomized trials (2026)
  3. ASAS. Official DAPSA44 calculator and source publications
  4. Healy and Helliwell. Leeds Enthesitis Index development (2008)
  5. Di Matteo et al. DEUS Enthesitis Index (2025)
  6. Helliwell et al. Development of a dactylitis assessment tool (2005)

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Peripheral SpASpondyloarthritis